Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic

Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic

Introduction. The renin-angiotensin system (RAS) is the main target of neurohumoral therapy in heart failure with reduced ejection fraction (HFrEF) effectively reducing mortality. Reasonably, renin might serve as a biomarker for risk prediction and therapy response. Renin indeed bears some additiona...

Full description

Bibliographic Details
Main Authors:	Emilie Han, Suriya Prausmüller, Annika Weidenhammer, Georg Spinka, Henrike Arfsten, Philipp E. Bartko, Georg Goliasch, Martin Hülsmann, Noemi Pavo
Format:	Article
Language:	English
Published:	SAGE Publications 2023-01-01
Series:	Journal of the Renin-Angiotensin-Aldosterone System
Online Access:	http://dx.doi.org/10.1155/2023/8883145

Similar Items

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
by: Suriya Prausmüller, et al.
Published: (2020-06-01)

CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF
by: Annika Weidenhammer, et al.
Published: (2023-12-01)

Neutrophil Activation/Maturation Markers in Chronic Heart Failure with Reduced Ejection Fraction
by: Suriya Prausmüller, et al.
Published: (2022-02-01)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
by: Andreas Spannbauer, et al.
Published: (2019-08-01)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
by: Leonie Grossekettler, et al.
Published: (2020-05-01)

Malnutrition outweighs the effect of the obesity paradox
by: Suriya Prausmüller, et al.
Published: (2022-06-01)

Different determinants of exercise capacity in HFpEF compared to HFrEF
by: Arlind Batalli, et al.
Published: (2017-04-01)

Soluble (Pro)Renin Receptor Levels Are Regulated by Plasma Renin Activity and Correlated with Edema in Mice and Humans with HFrEF
by: Inna P. Gladysheva, et al.
Published: (2022-08-01)

Neprilysin as a Biomarker: Challenges and Opportunities
by: Noemi Pavo, et al.
Published: (2020-08-01)

Prevalence of Prediabetes and Newly diagnosed Diabetes in Patients with HFpEF and HFrEF
by: Ahmad ELSharawy, et al.
Published: (2024-01-01)

Neprilysin inhibition does not alter dynamic of proenkephalin‐A 119‐159 and pro‐substance P in heart failure
by: Henrike Arfsten, et al.
Published: (2021-06-01)

Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus
by: Suriya Prausmüller, et al.
Published: (2021-02-01)

Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population
by: Balázs Solymossi, et al.
Published: (2024-04-01)

Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF)
by: Faris Zvizdić, et al.
Published: (2021-08-01)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
by: Mohammed Al-Jarallah, et al.
Published: (2020-01-01)

An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation
by: Georg Spinka, et al.
Published: (2020-11-01)

ARNI Versus Perindopril for Remodeling in HFrEF. A Cohort Study
by: Noor Muhammad Azlan Shah Bin Atan MBBS, et al.
Published: (2023-08-01)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
by: Zheng Li, et al.
Published: (2023-02-01)

Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF
by: Artan Ahmeti, et al.
Published: (2017-10-01)

On- vs. Off-Pump CABG in Heart Failure Patients with Reduced Ejection Fraction (HFrEF): A Multicenter Analysis
by: Christian Jörg Rustenbach, et al.
Published: (2023-11-01)

Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
by: Ghader Mohammadnezhad, et al.
Published: (2022-12-01)

Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF
by: Massimo Iacoviello, et al.
Published: (2024-02-01)

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
by: Jan Benes, et al.
Published: (2023-09-01)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
by: Volker Adams, et al.
Published: (2021-08-01)

The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes
by: Melissa A. Lyle, et al.
Published: (2020-01-01)

Relevance of Neutrophil Neprilysin in Heart Failure
by: Suriya Prausmüller, et al.
Published: (2021-10-01)

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients
by: Alfonso Campanile, et al.
Published: (2023-05-01)

Echocardiographic Parameters as Predictors for the Efficiency of Resynchronization Therapy in Patients with Dilated Cardiomyopathy and HFrEF
by: Silvius-Alexandru Pescariu, et al.
Published: (2021-12-01)

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients
by: Chia‐Te Liao, et al.
Published: (2021-10-01)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
by: Judit Simon, et al.
Published: (2019-06-01)

The Sub-Analysis of HFmrEF and HFrEF Group in CORE-HF Registry : When being Good is Not Enough
by: Irnizarifka Irnizarifka, et al.
Published: (2023-10-01)

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
by: Steven J. Simmonds, et al.
Published: (2020-01-01)

Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF)
by: Sungji Cho, et al.
Published: (2024-02-01)

Effects of neurohormonal antagonists on blood pressure in patients with heart failure with reduced ejection fraction (HFrEF): a systematic review protocol
by: Rama Krishna Guggilla, et al.
Published: (2020-08-01)

Safety and efficacy of renal denervation in patients with heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis
by: Zhiqiu Xia, et al.
Published: (2022-01-01)

Effect of pueraria on left ventricular remodelling in HFrEF: A systematic review and meta-analysis.
by: Lipeng Shi, et al.
Published: (2023-01-01)

Effect of pueraria on left ventricular remodelling in HFrEF: A systematic review and meta-analysis
by: Lipeng Shi, et al.
Published: (2023-01-01)

The Predictive Value of Eosinophil Indices for Major Cardiovascular Events in Patients with Acute Decompensated HFrEF
by: Aslı Vural, et al.
Published: (2022-10-01)

Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
by: Matteo Pagnesi, et al.
Published: (2022-01-01)